- Price
- $183.99
- Day
- +1.28%
- Mkt Cap
- $11.81B
- 52W Range
- $101.00 – $247.49
- Volume
- 449.4K
- Beta
- 0.87
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Do Options Traders Know Something About DaVita Stock We Don't?
Investors need to pay close attention to DVA stock based on the movements in the options market lately.
Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
In fact, it's a healthcare company. It is a strong player in its chosen niche.
Alebund Pharmaceuticals Announces 2026 Interim Results
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.